This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Oncothyreon, Amag, Keryx Hate Mail

@BioRunner59 asks, "Will you apologize when perifosine works?"

Yes, absolutely. I understand what's at stake. Part of the responsibility of my job is to hold myself accountable for the predictions and analysis I provide. If I get something wrong, I own it. No one is right 100% of the time. Getting stuff wrong is part of this game, but it's important to acknowledge errors and learn from them.

BioRunner tweeted his question to me because he thinks my prediction of failure for Keryx Biopharmaceuticals' (KERX - Get Report) phase III study of perifosine in colon cancer is going to be one of those calls I get wrong. I disagree, but we'll see what happens when the results are released, hopefully next month. Right or wrong, you'll hear from me.

Now, for our hate-mail segment, also related to Keryx and perifosine partner, Aeterna Zentaris (AEZS - Get Report).

Bbrewski writes, "You are just Wall Street Scum and when Peri[fosine] hits I hope you are man enough to admit you cost a lot of investors major money and you should go to jail, just because you are a coward behind some big firm, we will get the last laugh, because we know what we own and you do not. So let it be written so let it be done you coward behind a key board!!!!!Mark this post I will !!!!!"

Stephen W. writes, "Don't know to break this to you, but the only investing writer whose credibility is gone is looking back at you in the mirror. When you decide to stop shilling for Big Short, that will change. Not before, not unless, not until. Ta-ta!"

MontyM asks, " Discovery Labs (DSCO), what happened?"

The good news: On the fifth attempt spanning eight years, Discovery was finally able to secure FDA approval for Surfaxin as a new treatment for respiratory distress syndrome in premature infants.

The bad news: Discovery is almost broke and needs to raise money to start selling Surfaxin later this year. Investors knew about Discovery's weak financial position before Surfaxin was approved, setting up the stock for a quick but short-lived pop on approval. After that, a sell off was inevitable as investors/traders either a) took quick profits, or b) took quick profits and tried to find shares to short. Investors don't
3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DSCO $2.69 -2.54%
AEZS $4.05 0.00%
AMAG $26.52 0.00%
KERX $5.44 0.00%
ONTY $1.30 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs